Stock Market & Financial Investment News

News For PFE;ENDP From The Last 14 Days Check below for free stories on PFE;ENDP the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. << 1 | 2 | all recent news | >> May 22, 2013 08:59 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:06 EDT PFE Zoetis comments on Pfizer’s split-off plans for remaining interest Subscribe for More Information 08:04 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information 08:02 EDT PFE Pfizer announces plan to split-off remainder of Zoetis Subscribe for More Information May 21, 2013 07:16 EDT PFE Pfizer management to meet with Leerink Subscribe for More Information May 20, 2013 17:04 EDT PFE Pfizer discontinues phase 3 study of inotuzumab ozogamicin Subscribe for More Information May 17, 2013 11:53 EDT ENDP Options with decreasing implied volatility: SGMO ARNA CSC ENDP Subscribe for More Information May 16, 2013 10:03 EDT ENDP On The Fly: Analyst Upgrade Summary Subscribe for More Information 08:55 EDT PFE BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call Subscribe for More Information 08:27 EDT ENDP Endo Health upgraded to Buy from Neutral at Buckingham Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41. May 13, 2013 09:27 EDT ENDP Endo Health downgraded to Market Perform from Outperform at William Blair 09:25 EDT ENDP On The Fly: Pre-market Movers Subscribe for More Information 09:04 EDT ENDP Endo Health falls 4.8% Endo Health is down 4.8%, or $1.67, to $33.30 08:13 EDT ENDP Endo Health price target lowered to $31 from $35 at Susquehanna Subscribe for More Information 07:49 EDT ENDP FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. 07:45 EDT ENDP Endo Health price target lowered to $36 from $42 at Stifel Subscribe for More Information 07:32 EDT ENDP Endo Health downgraded to Sell from Neutral at Lazard Capital Subscribe for More Information 07:20 EDT ENDP Endo Health price target lowered to $37 from $47 at Jefferies Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated. 06:48 EDT ENDP Endo Health downgraded to Fair Value from Buy at CRT Capital Subscribe for More Information May 10, 2013 16:59 EDT ENDP Endo Health says FDA denial could cut FY13 adjusted EPS by 55c Subscribe for More Information 16:29 EDT PFE On The Fly: Closing Wrap Subscribe for More Information 15:45 EDT ENDP Endo Health trading halted, pending news 15:44 EDT ENDP Endo Health denied petition to block Opana ER generics Subscribe for More Information 12:31 EDT PFE On The Fly: Midday Wrap Subscribe for More Information 11:48 EDT PFE Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information 09:21 EDT PFE On The Fly: Pre-market Movers Subscribe for More Information 08:08 EDT PFE Pain Therapeutics discloses Pfizer reassessing continued Remoxy partnership Pain Therapeutics (PTIE) disclosed a letter its CEO was sent from partner Pfizer (PFE) in which the drug maker said it is reassessing its endorsement of the Remoxy program "given the years of delay, additional cost incurred to bring the program to this point and development work left in the program." Pfizer said it will be reaching out to Pain Therapeutics "shortly" to have a confidential discussion about the terms of the companies' contractual agreement over the pain drug. Pfizer that it appears there is a regulatory pathway forward for Remoxy, but that the company does not expect to respond to submit a Complete Response letter for Remoxy to the FDA before mid-2015. Pfizer added in its letter to Pain Therapeutics "no final decision has been made at this time" on how it will proceed with the Remoxy development program. Shares of Pain Therapeutics fell 47% to $2.81 in pre-market trading following the disclosure of the correspondence. 07:46 EDT PFE DURECT says additional clinical studies needed for Remoxy DURECT (DRRX) announced that Pfizer (PFE) has provided an update on Remoxy in a regulatory filing. Pfizer's disclosure included: "We have been working to address the issues raised in the letter, which primarily relate to manufacturing. We met with the FDA in March 2013 to discuss our plan to address the June 2011 "complete response" letter. We received written guidance from the FDA in May regarding required next steps, including additional clinical studies, to address the letter. Based on this guidance, we are considering our options with respect to Remoxy. If we elect to continue development of Remoxy, we would not expect to submit a response to the 'complete response' letter before mid-2015." DURECT said it understands from Pfizer that additional clinical studies are necessary and include, in part, a pivotal bioequivalence study with the modified formulation to bridge to the clinical data conducted with the original formulation, as well as an abuse potential study with the modified Remoxy formulation. Remoxy is based on DURECT's ORADUR technology. Shares of Pfizer's Remoxy partner Pain Therapeutics (PTIE) are down 56% in pre-market trading, while shares of DURECT are down 13%, or 20c, to $1.39. May 9, 2013 16:52 EDT ENDP BDSI's Phase 3 trials for BEMA Buprenorphine to finish late 2013 or early 2014 Subscribe for More Information 16:44 EDT ENDP Blue Ridge Capital reports 5.98% passive stake in Endo Health Subscribe for More Information 10:17 EDT PFE Shire trades higher in London amid takeover chatter, Guardian says Subscribe for More Information << 1 | 2 | all recent news | >> Sign up for a free trial to see the rest of the stories you've been missing.